Le Lézard
Classified in: Health, Science and technology
Subjects: EXE, BLK, DEI

NIIMBL Is Now Accepting Applications for the 2024 NIIMBL eXperience Cohort After Awarding $500k to Expand Program


NEWARK, Del., Oct. 17, 2023 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has awarded approximately $500k in funding to launch the 2024 NIIMBL eXperience program in five locations across the United States. The application period is now open for the following locations: Albany College (ACPHS)- New York, Biomanufacturing Training Center at North Carolina State University, Thomas Jefferson University- Pennsylvania, Santa Clara University- California, and the University of Houston-Texas.

The NIIMBL eXperience program is an all-expenses paid biopharmaceutical manufacturing immersion program for university and community college students who have completed their first or second year of study. Specifically designed for Black, Latinx, and Indigenous students, the program strives to diversify the school-to-industry pipeline for the biopharmaceutical manufacturing industry.

"After piloting an expansion effort last year, we quickly realized that we could make a larger impact by moving into a regional model. That model enabled us to reach more students in one year than what we reached in the prior four years combined," said John Balchunas, NIIMBL workforce development director. "Our hosts are excited and equipped to reach students across the country making the introduction to the biopharmaceutical manufacturing industry more tangible than ever before through the eXperience," adds Balchunas.

Participating students will visit leading biopharma companies, tour manufacturing facilities, and receive hands-on introductions to state-of-the-art equipment. They also will become familiar with the types of organizations in the biopharmaceutical manufacturing ecosystem and the role they play in bringing life-saving treatments to patients. Students are encouraged to apply to the region that best aligns with their residence. Academic organizations are also encouraged to share this application process with students in their network.

"I think the entire experience gave me courage and an exceptional look into the real world of engineering and science. I've never been able to get exposure to these facilities and devices, and I think understanding the background of the people clad in lab coats and what they studied helped give me more options and hope that I can find my path while I study," 2023 NIIMBL eXperience ACPHS participant.

In August 2023, NIIMBL issued a Request for Applications seeking proposals from NIIMBL members to expand the eXperience program across the United States. This is the second year that NIIMBL has expanded their eXperience program to reach more students across a broader range of geographic locations and communities. Last year, 41 students participated in the program at three locations across the country. This year, NIIMBL is prepared to accept up to 75 students into the 2024 cohort.

Visit NIIMBL.org to learn more about the NIIMBL eXperience program and to apply for the 2024 cohort.

*All funding is subject to project agreement negotiations. 

About NIIMBL

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry. NIIMBL is part of Manufacturing USA®, a diverse network of federally-sponsored manufacturing innovation institutes, and is funded through a cooperative agreement with the National Institute of Standards and Technology (NIST) in the U.S. Department of Commerce with significant additional support from its members.

Contact:
News Media
Maria X. Chacon
Director of Marketing and Communications
302-831-2337
[email protected]

SOURCE National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)


These press releases may also interest you

at 05:00
The global Specialty Enzymes Market size is estimated to be valued at USD 6.1 billion in 2024 and is projected to reach USD 9.2 billion by 2029, recording a CAGR of 8.5% from 2024 to 2029 according to a report published by MarketsandMarketstm. The...

at 05:00
Kvantify, a leading quantum software start-up, has announced the successful closure of a EUR 10 million seed round. This funding will enable Kvantify to strengthen its position as a global leader in quantum computing, with an initial focus on...

at 04:37
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cytotoxic Drugs and HPAPI Manufacturing  Market- (Type of Product (HPAPI and highly potent finished dosage form), Company Size (Small, Mid-sized, Large,...

at 04:32
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC...

at 04:32
The Compound Annual Growth Rate (CAGR) measures how much an investment grows each year, on average, over a period. It helps to show the overall trend by smoothing out the ups and downs. Recently, BCC Research predicted that a certain industry would...

at 04:15
During its annual event "BIG UP", French Tech Saint-Etienne Lyon awarded the BIG Start-up of the Year trophy, honoring a start-up that exemplifies the region's innovation and richness. French Tech Saint-Etienne Lyon, a non-profit association...



News published on and distributed by: